Betteromics’ Post

As with most of our posts, this is less about us than it is an attempt to engage, educate, learn, and share ideas around topics of relevance to the industries we serve. We are looking forward to learning!

Check out my blog post on How AI is Transforming Pharmacovigilance Through Safety Databases! https://wix.to/vFNYDs8 #newblogpost

Same prompt, different results?   Are you sometimes looking for an answer in a PV-related topic and don't know where to start looking?   You are browsing through all the GVP documents… ctrl+F… nothing, ctrl+F… nothing.   It can be exhausting.   And time-consuming.   We prompted various AI Large Language Models with pharmacovigilance-related queries and documented their answers.   Understanding AI capabilities in pharmacovigilance can revolutionize how we handle drug safety data.   What are your thoughts on the potential of AI in pharmacovigilance? Which AI model impressed you the most? Please share your thoughts.   Follow us for more industry news and education.   And take your PV to the #NextLevel! 🚀

Have you ever wondered how often the RMP should be updated following the EU GVP? Look at what different Large Language Models say about it: ChatGPT 3.5 ChatGPT 4.0 Google Bard aka Gemini Perplexity NextPV custom GPT - Pocket GVP consultant Follow us for more industry news and education. And take your PV to the #NextLevel! 🚀

Our MD, Ricky Martin recently attended the 2024 MHRA Good Pharmacovigilance Practice (GPvP) symposium which looked into GPvP inspection non-compliance, metrics and trends and regulatory updates. The discussion included all the below... 🔹GPvP requirements and good practice in the UK 🔸Latest trends in pharmacovigilance non-compliance identified during MHRA inspections 🔹UK regulatory updates and changes 🔸Regulator perspectives on hot topics in pharmacovigilance What we found particularly interesting was the discussion surrounding some hot topics in pharmacovigilance, including the use of AI and machine learning (ML) technologies. What do you think? Is your organisation currently using or exploring the use of AI/ML in pharmacovigilance? To find out more on what we learnt, click the link below and read our latest blog 💻 David Powell Greg King Ben Hamlin Hayley Swords Ben Vicentuan Luke Webber #scienceblog #Pharmacovigilance #GPvP

Check out my blog post https://wix.to/fnodn5G #newblogpostCheck out our blog post about "How AI Transforms Literature Monitoring in Pharmacovigilance" https://wix.to/CJUNd6X #newblogpost How AI Transforms Literature Monitoring in Pharmacovigilance

Fascinating Insights from the MHRA on AI in Pharmacovigilance! 🚀 #GPvP2024 #AIinPV #Pharmacovigilance At the GPvP Symposium in February, the MHRA shared some eye-opening data on the adoption of AI within PV, showcasing the transformative impact of AI on drug safety. Key numbers in % of organizations who were a part of the symposium: 43% of organizations are now leveraging AI to collect and collate ADR, including Medical Information. 32% have integrated AI into ICSR management and regulatory submissions, 20% are utilizing AI in signal management, highlighting AI's capability to detect potential safety signals faster and more reliably. 9% of organizations use AI to aggregate reports It’s crucial for us to stay informed and adapt to these emerging technologies. What are your thoughts on the future of AI in Pharmacovigilance? How do you see these trends evolving in the next few years? #DigitalHealth #AI #Pharmacovigilance #DrugSafety

Another great ISPE Ireland Affiliate event yesterday in the Rochestown Park Hotel. The days subject was "Compliant digital solutions & paradigms for the future". We were treated to an excellent set of presentations from leading pharmas, academia as well as a great presentation from the European Medicines Agency's Ib Alstrup on the regulatory compliance perspective on using AI in critical GxP applications. Ib outlined a suggested criteria for using AI/ML algorithms in GxP. An important point he noted that they look for when assessing AI/ML use in pharma was 'What evidence exists that no part of the dataset used to test the algorithm has previously been used to train or validate (optimize) the same algorithm, or originates from the same subjects?' Interested parties should follow his link (from his LinkedIn page) to the list of questions that companies should ask themselves. It is an excellent resource. Always a great day to meet up with friends and colleagues old and new. A nice chicken dinner as well! Amelie O'Brien Joe Lyons Peter Blennerhassett Arnoldo Müller Dr. Eva Kelly Enhanced Information Solutions (EIS) ERA Sciences Business Platforms Clarke Analytics Ltd. Philip Gammell #pharma #regulators #ai #machinelearning #csv #csa #dataintegrity

Brilliant catching up with you Dave Clarke and really great to hear how well things are going. Data analytics is game changing for many reasons but for me the ability to analyse vast data sets from disparate often siloed sources means we identify patterns rapidly and have rapidly moved on validating clinical hypotheses over the last few years And yes game changing for patients. #patientcentric #dataintegrity

EMA’s guiding principles for the use of LLMs. The European Medicines Agency recently issued their guidelines around the use of Large Language Models (LLMs) in regulatory science and for regulatory authorities. This is obviously a long-awaited first step towards an accepted path for the positive introduction of LLMs and generative AI into everyday healthcare and pharmacovigilance activities. The guidance covers a range of topics including: · Safe usage · Ethical considerations ·  Data input considerations including prompting ·  Training data considerations ·  Governance The use of AI has of course many areas that will make concrete determinations difficult or impossible, and the guidance acknowledges it’s ‘living document’ status, but it goes a long way to highlight best practice thinking and structure on the subject as it evolves. This is also very relevant to Delta PV as we are currently collaborating with a US partner on an AI enabled case intake tool that can vastly reduce processing times, so we are particularly pleased to see this move forwards. More news on this to come shortly! You can find information on the guidance here: https://lnkd.in/d9sZsuyT And the guidance document itself here: https://lnkd.in/e-FZd-r8 For information about our pharmacovigilance solutions here: https://lnkd.in/gjAusNrF And information about LITSIS system here: https://lnkd.in/gDJRDzj6 Please share this post to spread the news and help Delta PV keep growing. Delta PV creates lean, efficient, and effective pharmacovigilance and safety solutions across Europe, CIS, EAEU, Africa, MENA, and APAC. See how we can support you at www.deltapv.com #ArtificialIntelligence #AI #LLM #Pharmacovigilance #ClinicalSafety #PVTechnology